PRESS RELEASES

2021 Interim Results——Successful Turnaround to Profit-making with Record-High Turnover Expanding R&D Activity in Nanobody Drug to Diversify Product Portfolio

2021 Interim Results Successful Turnaround to Profit-making with Record-High Turnover Expanding R&D Activity in Nanobody Drug to Diversify Product Portfolio

2021-08-27

View details

UNI-BIO SCIENCE GROUP LIMITED POSITIVE PROFIT ALERT

2021-08-10

View details

2020 Annual Results Successful Expansion into Pharmaceutical E-commerce，Driving Sales Growth of GeneTime®，Achived Significant Progress towards Pipeline Products and Boshutai® was Granted Approval for Marketing in China

2021-03-30

View details

Uni-Bio Science Group and DotBio Announce Partnership to Co-Develop multi-specific DotBodies for people with retinal diseases

2021-03-10

View details

The National Medical Products Administration Granted Marketing Approval for BOSHUTAI® (Acarbose Tablets) in China

2020-12-16

View details

z6com尊龙凯时官网

Media

PRESS RELEASES

2021 Interim Results——Successful Turnaround to Profit-making with Record-High Turnover Expanding R&D Activity in Nanobody Drug to Diversify Product Portfolio

UNI-BIO SCIENCE GROUP LIMITED POSITIVE PROFIT ALERT

2020 Annual Results Successful Expansion into Pharmaceutical E-commerce，Driving Sales Growth of GeneTime®，Achived Significant Progress towards Pipeline Products and Boshutai® was Granted Approval for Marketing in China

Uni-Bio Science Group and DotBio Announce Partnership to Co-Develop multi-specific DotBodies for people with retinal diseases

The National Medical Products Administration Granted Marketing Approval for BOSHUTAI® (Acarbose Tablets) in China

Copyright ©2022 Uni-Bio Science Group Ltd.

z6com尊龙凯时官网

Media

PRESS RELEASES

2021 Interim Results——Successful Turnaround to Profit-making with Record-High Turnover Expanding R&D Activity in Nanobody Drug to Diversify Product Portfolio

UNI-BIO SCIENCE GROUP LIMITED POSITIVE PROFIT ALERT

2020 Annual Results Successful Expansion into Pharmaceutical E-commerce，Driving Sales Growth of GeneTime®，Achived Significant Progress towards Pipeline Products and Boshutai® was Granted Approval for Marketing in China

Uni-Bio Science Group and DotBio Announce Partnership to Co-Develop multi-specific DotBodies for people with retinal diseases

The National Medical Products Administration Granted Marketing Approval for BOSHUTAI® (Acarbose Tablets) in China

Copyright ©2022 Uni-Bio Science Group Ltd.

2021 Interim Results——Successful Turnaround to Profit-making with Record-High Turnover Expanding R&D Activity in Nanobody Drug to Diversify Product Portfolio

UNI-BIO SCIENCE GROUP LIMITED POSITIVE PROFIT ALERT

2020 Annual Results Successful Expansion into Pharmaceutical E-commerce，Driving Sales Growth of GeneTime®，Achived Significant Progress towards Pipeline Products and Boshutai® was Granted Approval for Marketing in China

Uni-Bio Science Group and DotBio Announce Partnership to Co-Develop multi-specific DotBodies for people with retinal diseases

The National Medical Products Administration Granted Marketing Approval for BOSHUTAI® (Acarbose Tablets) in China